Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 148

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C

Freedman, Neal D., Everhart, James E., Lindsay, Karen L., Ghany, Marc G., Curto, Teresa M., Shiffman, Mitchell L., Lee, William M., Lok, Anna S., Di Bisceglie, Adrian M., Bonkovsky, Herbert L., Hoefs, John C., Dienstag, Jules L., Morishima, Chihiro, Abnet, Christian C., Sinha, Rashmi·2009·Hepatology
DOI 10.1002/hep.23162
Open this paper in CoChat — free account

Abstract

Higher coffee consumption has been associated inversely with the incidence of chronic liver disease in population studies. We examined the relationship of coffee consumption with liver disease progression in individuals with advanced hepatitis C–related liver disease. Baseline coffee and tea intake were assessed in 766 participants of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had hepatitis C–related bridging fibrosis or cirrhosis on liver biopsy and failed to achieve a sustained virological response to peginterferon plus ribavirin treatment. Participants were followed for 3.8 years for clinical outcomes and, for those without cirrhosis, a 2-point increase in Ishak fibrosis score on protocol biopsies. At baseline, higher coffee consumption was associated with less severe steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assessment (HOMA2) score, and higher albumin (P < 0.05 for all). Two hundred thirty patients had outcomes. Outcome rates declined with increasing coffee intake: 11.1/100 person-years for none, 12.1 for less than 1 cup/day, 8.2 for 1 to fewer than 3 cups/day, and 6.3 for 3 or more cups/day (P-trend = 0.0011). Relative risks (95% confidence intervals) were 1.11 (0.76-1.61) for less than 1 cup/day; 0.70 (0.48-1.02) for 1 to fewer than 3 cups/day; and 0.47 (0.27-0.85) for 3 or more cups/day (P-trend = 0.0003) versus not drinking. Risk estimates did not vary by treatment assignment or cirrhosis status at baseline. Tea intake was not associated with outcomes. Conclusion: In a large prospective study of participants with advanced hepatitis C–related liver disease, regular coffee consumption was associated with lower rates of disease progression. (Hepatology 2009.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.23162

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 36

  1. Williams, 2006, Global challenges in liver disease., HEPATOLOGY, 44, 521, 10.1002/hep.21347 · DOI · Paper page
  2. Fried, 2002, Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection., N Engl J Med, 347, 975, 10.1056/NEJMoa020047 · DOI
  3. Arnesen, 1986, The Tromso Heart Study: distribution of, and determinants for, gammaglutamyltransferase in a freeliving population., Scand J Clin Lab Invest, 46, 63, 10.3109/00365518609086483 · DOI
  4. Casiglia, 1993, Unexpected effects of coffee consumption on liver enzymes., Eur J Epidemiol, 9, 293, 10.1007/BF00146266 · DOI
  5. Honjo, 2001, Coffee consumption and serum aminotransferases in middleaged Japanese men., J Clin Epidemiol, 54, 823, 10.1016/S0895-4356(01)00344-4 · DOI
  6. Klatsky, 2006, Coffee, cirrhosis, and transaminase enzymes., Arch Intern Med, 166, 1190, 10.1001/archinte.166.11.1190 · DOI
  7. Ruhl, 2005, Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States., Gastroenterology, 128, 24, 10.1053/j.gastro.2004.09.075 · DOI · Paper page
  8. Tanaka, 1998, Coffee consumption and decreased serum gammaglutamyltransferase and aminotransferase activities among male alcohol drinkers., Int J Epidemiol, 27, 438, 10.1093/ije/27.3.438 · DOI
  9. Corrao, 2001, Coffee, caffeine, and the risk of liver cirrhosis., Ann Epidemiol, 11, 458, 10.1016/S1047-2797(01)00223-X · DOI
  10. Gallus, 2002, Does coffee protect against liver cirrhosis?, Ann Epidemiol, 12, 202, 10.1016/S1047-2797(01)00304-0 · DOI
  11. Klatsky, 1993, Coffee, tea, and mortality., Ann Epidemiol, 3, 375, 10.1016/1047-2797(93)90064-B · DOI
  12. Tverdal, 2003, Coffee intake and mortality from liver cirrhosis., Ann Epidemiol, 13, 419, 10.1016/S1047-2797(02)00462-3 · DOI
  13. Ruhl, 2005, Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States., Gastroenterology, 129, 1928, 10.1053/j.gastro.2005.08.056 · DOI
  14. Larsson, 2007, Coffee consumption and risk of liver cancer: a metaanalysis., Gastroenterology, 132, 1740, 10.1053/j.gastro.2007.03.044 · DOI · Paper page
  15. Bravi, 2007, Coffee drinking and hepatocellular carcinoma risk: a metaanalysis., HEPATOLOGY, 46, 430, 10.1002/hep.21708 · DOI
  16. Gressner, 2008, Pharmacological application of caffeine inhibits TGFbetastimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD23dependent pathways., J Hepatol, 49, 758, 10.1016/j.jhep.2008.03.029 · DOI
  17. GomezRuiz, 2007, In vitro antioxidant activity of coffee compounds and their metabolites., J Agric Food Chem, 55, 6962, 10.1021/jf0710985 · DOI
  18. Lee, 2000, Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation., Clin Chim Acta, 295, 141, 10.1016/S0009-8981(00)00201-1 · DOI · Paper page
  19. Cavin, 2002, Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity., Food Chem Toxicol, 40, 1155, 10.1016/S0278-6915(02)00029-7 · DOI · Paper page
  20. Shapiro, 2006, Coffee and tea consumption and chronic liver disease., Gastroenterology, 130, 1931, 10.1053/j.gastro.2006.03.035 · DOI
  21. Di Bisceglie, 2008, Prolonged therapy of advanced chronic hepatitis C with lowdose peginterferon., N Engl J Med, 359, 2429, 10.1056/NEJMoa0707615 · DOI · Paper page
  22. Ishak, 1995, Histological grading and staging of chronic hepatitis., J Hepatol, 22, 696, 10.1016/0168-8278(95)80226-6 · DOI
  23. Block, 1992, Comparison of two dietary questionnaires validated against multiple dietary records collected during a 1year period., J Am Diet Assoc, 92, 686, 10.1016/S0002-8223(21)00707-0 · DOI · Paper page
  24. Ware, 1992, The MOS 36item shortform health survey (SF36). I. Conceptual framework and item selection., Med Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
  25. Cox, 1972, Regression models and lifetables., J R Stat Soc Series B Stat Methodol, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x · DOI · Paper page
  26. Ruhl, 2003, Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States., Gastroenterology, 124, 71, 10.1053/gast.2003.50004 · DOI
  27. Arion, 1997, Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6phosphatase., Arch Biochem Biophys, 339, 315, 10.1006/abbi.1996.9874 · DOI · Paper page
  28. Chou, 2002, Type I glycogen storage diseases: disorders of the glucose6phosphatase complex., Curr Mol Med, 2, 121, 10.2174/1566524024605798 · DOI
  29. Friedman, 2008, Mechanisms of hepatic fibrogenesis., Gastroenterology, 134, 1655, 10.1053/j.gastro.2008.03.003 · DOI · Paper page
  30. LopezGarcia, 2008, The relationship of coffee consumption with mortality., Ann Intern Med, 148, 904, 10.7326/0003-4819-148-12-200806170-00003 · DOI
  31. LopezGarcia, 2006, Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women., Am J Clin Nutr, 84, 888, 10.1093/ajcn/84.4.888 · DOI · Paper page
  32. Zampelas, 2004, Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study., Am J Clin Nutr, 80, 862, 10.1093/ajcn/80.4.862 · DOI
  33. Hosaka, 2001, Hepatocarcinogenesis inhibition by caffeine in ACI rats treated with 2acetylaminofluorene., Food Chem Toxicol, 39, 557, 10.1016/S0278-6915(00)00175-7 · DOI
  34. Heilbrun, 1986, Black tea consumption and cancer risk: a prospective study., Br J Cancer, 54, 677, 10.1038/bjc.1986.226 · DOI
  35. Inoue, 2005, Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan., J Natl Cancer Inst, 97, 293, 10.1093/jnci/dji040 · DOI
  36. Montella, 2007, Coffee and tea consumption and risk of hepatocellular carcinoma in Italy., Int J Cancer, 120, 1555, 10.1002/ijc.22509 · DOI

Cited by

See all 148

Metadata

Authors
Freedman, N. D., Everhart, J. E., Lindsay, K. L., Ghany, M. G., Curto, T. M., Shiffman, M. L., Lee, W. M., Lok, A. S., Di Bisceglie, A. M., Bonkovsky, H. L., Hoefs, J. C., Dienstag, J. L., Morishima, C., Abnet, C. C., & Sinha, R.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2009-11
Volume
50
Issue
5
Pages
1360-1369
ISSN
0270-9139
DOI
10.1002/hep.23162
Cited by
148
References
6
Language
en
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2130 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.